People with kidney disease that have the APOL1 risk variant are at a greater risk for developing protein in their urine and chronic kidney disease. This research study is being done to determine if the investigational drug, VX-147 can slow or stop the worsening of kidney function as well as target the underlying cause of kidney disease.
Do you have Chronic Kidney Disease that is due to Type 2 Diabetes? You may be able to take part in a research study to help learn about the safety and impact of a study treatment that is injected into one of your kidneys.
Do you have stage 3 or 4 Chronic Kidney Disease that is due to Congenital Anomalies of the Kidney or Urinary Tract? You may be able to take part in a research study to help learn about the safety and impact of a study treatment that is injected into one of your kidneys.
You are participating in a clinical research study to investigate whether voclosporin (the study drug) added to standard treatment is able to reduce Lupus Nephritis disease activity in adolescents. This study involves 24 weeks of treatment and you will be required to follow specific instructions of the study as explained by your study doctor and team
Have you been infected with COVID-19? Are you a solid organ transplant recipient? Have you or your child received a COVID-19 vaccine or are planning to receive one? If so, you may be eligible to participate in a research study that will assess your immune response to COVID-19 infection or vaccination over a 5 year period. We are looking for children and adults aged 7-95 years, and plan to collect blood every 2-6 months over the study period. (Compensation provided for the first year).
Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this trial, the researchers want to learn if finerenone helps to slow down the worsening of the participants' non-diabetic CKD compared to a placebo. A placebo looks like a trial treatment but does not have any medicine in it. The trial will include about 1,580 men and women who are at least 18 years old.
The purpose of the EPPIK study is to gain further experience on the use of sparsentan in children.
We still have a lot to learn about why people develop glomerular disease and what the best medicines are to treat these diseases. Diabetes is a common, chronic illness and many people with glomerular disease also have diabetes. Currently, there is no information telling us the best ways to treat patients with both diabetes and glomerular disease, or how to counsel them about prognosis and risks for complications. This substudy of the Cure Glomerulopathy Network brings together information and laboratory specimens from patients with diabetes and glomerular disease to speed up and improve health research for their care.
The study tests the safety and efficacy of a new type of drug, administered by intravenous infusion, for the treatment of lupus nephritis or IgA Nephropathy. You might be on the drug or on the placebo (no active drug ) and will help to figure out if this new drug is a good alternative or complement to existing drugs.
The CureGN Network acts as a "library" of data for investigators across the world to use to help us ask the following questions: 1) What is the disease?; 2) Why did it happen to me?; 3) Can it be passed down to my family members?; 4) What treatments work the best with the least side effects?